Pharmaceutical firm CorMedix misses Q4 profit expectations, reiterates 2026 revenue forecast

CorMedix

05/03/2026 12:39

Corrects Q4 Operating Expenses figure in Key Details table to $48.18 mln from -$48.18 mln

Overview

Biopharmaceutical firm's Q4 2025 net revenue was $128.6 mln, driven by DefenCath sales

Q4 net income of $14 mln missed analyst expectations

Company announced $75 mln share repurchase program

Outlook

CorMedix expects 2026 net revenue between $300 mln and $320 mln

Company projects 2026 adjusted EBITDA between $100 mln and $125 mln

CorMedix anticipates Phase 3 ReSPECT study data in Q2 2026

Result Drivers

DEFENCATH SALES - Q4 net revenue of $128.6 mln largely driven by DefenCath sales, contributing $91.2 mln

MELINTA ACQUISITION - Melinta portfolio contributed $37.4 mln to Q4 revenue, marking first full quarter post-acquisition

INCREASED OPERATING EXPENSES - Q4 operating expenses rose to $48.2 mln, driven by Melinta acquisition costs and R&D investments

Company press release: ID:nGNX27NWYd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
Miss
$0.16
$0.82 (7 Analysts)
Q4 Net Income
Miss
$14.02 mln
$68.24 mln (7 Analysts)
Q4 Basic EPS
$0.18
Q4 Operating Expenses
$48.18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for CorMedix Inc is $15.00, about 110.7% above its March 4 closing price of $7.12

The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 4 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)